Treos Bio to Present New Clinical Data on Off-the-Shelf Peptide Immunotherapy for Colorectal Cancer at 2024 ASCO Annual Meeting
2024年5月8日 - 8:45PM
Treos Bio, a clinical stage biotechnology company using data
science and proprietary biomarkers to develop precision peptide
immunotherapies, said investigators will present new results from a
phase 2 trial of the company’s lead product candidate PolyPEPI1018
in combination with Roche’s PD-L1 inhibitor atezolizumab in
patients with late-stage microsatellite stable metastatic
colorectal cancer at the 2024 ASCO Annual Meeting.
Colorectal cancer (CRC) is the third most common
cancer and the second leading cause of cancer-related deaths
worldwide, according to the World Health Organization. In the
United States, there are approximately 1.4 million people living
with colorectal cancer, according to the National Cancer Institute.
Current treatments for CRC include surgery and chemotherapy in
early stages of disease and chemotherapy, biologics and targeted
therapies in later stages. Microsatellite Stable (MSS) CRC accounts
for approximately 85 percent of all colorectal cancers and nearly
all cases of metastatic CRC (mCRC). Patients with MSS CRC do not
benefit from available immunotherapies.
PolyPEPI1018, Treos’ lead product candidate, is an
off-the-shelf immunotherapy in clinical development for the
treatment of metastatic colorectal cancer, co-developed with a
candidate companion diagnostic. The therapy is in development as a
first-line maintenance therapy and as a third line treatment. The
companion diagnostic uses Treos’ proprietary PASCal computational
tool to identify Personal EPItopes (PEPIs) that are likely to
induce antigen-specific T Cell responses in a patient.
Investigators will present a poster with new data
from OBERTO 301, a multicenter, open label, phase 2 trial
evaluating the combination treatment of PolyPEPI1018 and
atezolizumab in patients with MSS mCRC who have progressed on two
or three prior treatment regimens. The primary endpoint of the
study is incidence and severity of treatment related adverse events
and secondary endpoints include objective response rate, duration
of response, progression-free survival, and overall survival.
“We are highly encouraged by the consistency
observed across three clinical trials in MSS metastatic colorectal
cancer in different settings and the unique ability of PolyPEPI1018
to turn ‘cold’ tumors into ‘hot’ tumors,” said Christopher C.
Gallen, M.D., Ph.D., CEO of Treos Bio.
About Treos Bio LimitedTreos Bio
develops precision peptide cancer immunotherapies combined with
novel biomarkers using proprietary computational data science
integrating HLA genetics, tumor profile, and clinical outcome of
thousands of real subjects. Treos has conducted three clinical
trials in the United States and the European Union of its lead
candidate, PolyPEPI1018, an off-the-shelf immunotherapy for the
treatment of metastatic colorectal cancer. Treos has completed
preclinical development of additional off-the-shelf immunotherapies
in ovarian, breast, bladder, gastric, lung cancers, and melanoma.
The Company is also developing off-the-shelf immunotherapies
personalized to an individual patient’s HLA genotype for several
types of solid tumors. Treos has raised $45 million to
date. More information can be found
at www.treosbio.com.
Contact:Daniel LevineLevine Media
Groupdanny@levinemediagroup.com(510) 280-5405